• 한국미생물·생명공학회지
• /
• 제23권5호
• /
• pp.599-601
• /
• 1995

A cytotoxic compound, MCHS-4, was isolated from the mycelium of Streptomyces T70 and identified as manumycin A. The compound showed significant cytotoxicity against human gastric carcinoma cell line, SNU-1 and human hepatocellular cell line, SNU-354.

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 1988년도 제27차 춘계학술대회
• /
• pp.142.1-142.1
• /
• 1988

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 1992년도 제31차 춘계학술대회
• /
• pp.194.1-194.1
• /
• 1992

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 1995년도 제34차 춘계학술대회 초록집
• /
• pp.201-201
• /
• 1995

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 1991년도 제30차 춘계학술대회
• /
• pp.158.2-159
• /
• 1991

• Korean Journal of Radiology
• /
• 제24권1호
• /
• pp.6-9
• /
• 2023

• Korean Journal of Radiology
• /
• 제24권1호
• /
• pp.10-14
• /
• 2023

• 대한한방내과학회지
• /
• 제41권3호
• /
• pp.447-456
• /
• 2020

Objectives: This review aimed to present the characteristics of hepatocellular cancer patients treated by Korean medicine. Methods: Sixty hepatocellular cancer patients in a Korean medicine hospital from July 2012 to December 2019 were studied. We evaluated the general characteristics, overall therapies, and chief complaints of the patients. Results: Of the patients, 55% were stage IV, and Korean medicine was accompanied by conventional treatments, such as chemotherapy, operation, and transarterial chemoembolization. An average number of hepatocellular cancer patients had admitted to the hospital. The patients' chief complaints were dyspnea, general weakness, abdominal discomfort, and cancer-related pain. Conclusions: This study illustrates the general characteristics of hepatocellular cancer patients on Korean medicine treatments. These findings suggest that further investigations with a rigorous study design and more participants are needed.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권9호
• /
• pp.4423-4426
• /
• 2012

Aim: XRCC1 and XPD are two major repair genes involved in nucleotide excision repair (NER), which is reported to be associated with risk of several cancers. We explored the association of XRCC1 and XPD polymorphisms with the risk of HCC. Methods: A total of 410 cases with HCC and 410 health controls were collected. XRCC1 Arg194Trp, XRCC1 Arg399Gln, XPD Lys751Gln and XPD Asp312Asn genotyping was performed by duplex polymerase-chain-reaction with the confronting-two-pair primer (PCR-CTPP) method. Results: XRCC1 194Trp/Trp was strongly significantly associated with an increased risk of HCC cancer when compared with the wide-type genotype (OR=2.26, 95% CI=(1.23-5.38). Individuals carrying the XRCC1 399Gln/Gln showed increased risk of HCC (OR=1.74, 95%CI=1.06-2.74). The XPD 751Gln/Gln and Gln allele genotype were associated with strong elevated susceptibility to HCC (OR=3.51 and 1.42, respectively). Conclusion: These results suggest that polymorphisms in XRCC1 and XPD may have functional significance in risk of HCC.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권5호
• /
• pp.1725-1728
• /
• 2015

Objective: To explore effects of paclitaxel-loaded poly lactic-co-glycolic acid (PLGA) particles on the viability of human hepatocellular carcinoma (HCC) HepG2 cells. Materials and Methods: The viability of HepG2 cells was assessed using MTT under different concentrations of prepared paclitaxel-loaded particles and paclitaxel (6.25, 12.5, 25, 50, and 100 mg/L), and apoptosis was analyzed using Hochest33342/Annexin V-FITC/PI combined with an IN Cell Analyzer 2000. Results: Paxlitaxel-loaded nanoparticles were characterized by narrow particle size distribution (158.6 nm average particle size). The survival rate of HepG2 cells exposed to paclitaxel-loaded PLGA particles decreased with the increase of concentration and time period (P<0.01 or P<0.05), the dose- and time-dependence indicating sustained release (P<0.05). Moreover, apoptosis of HepG2 cells was induced, again with an obvious dose- and time-effect relationship (P<0.05). Conclusions: Paclitaxel-loaded PLGA particles can inhibit the proliferation and induce the apoptosis of HCC HepG2 cells. This new-type of paclitaxel carrier body is easily made and has low cost, good nanoparticle characterization and sustained release. Hence, paclitaxel-loaded PLGA particles deserve to be widely popularized in the clinic.